January 23, 2025

CSEM and TheraMe! revolutionize cancer therapy with personalized drug screening technology

  • TheraMe! is a Lausanne-based medtech start-up at the forefront of advancing cancer treatment
  • TheraMe! employs proprietary microfluidic technologies to test the efficacy of cancer drugs on patients' tumor cells to determine the best therapy recommendation before treatment starts.
  • Together with CSEM, TheraMe! develops an instrument that analyzes live tumor samples to identify the best drug combinations for individual cancer patients
Group of 7 persons, members of the CSEM and the TheraMe teams
© CSEM - (from left to right) Mehmet SEHIR, Vida VAFAIZADEH, Hana SAMET (all TheraMe!), Christoph MERTEN (EPFL), Gilles WEDER and Baris ATAKAN (both CSEM) and Ngoc-Hien DU (TheraMe!)

Related Press

Alithea team

16 May 2023

Democratizing RNA sequencing: A breakthrough in cost and efficiency

CSEM helped Alithea Genomics to create a technique that can handle hundreds of RNA samples in a single tube, resulting in a significant decrease in reagents and manual effort in the overall workflow....

Limula team

3 February 2023

Making personalized cancer therapies accessible to all

CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. ...

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....